Skip to main content

Table 1 Patient demographics and comparison of baseline characteristics of patients

From: Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization

 

All cohort (n = 83)

IL6 low (n = 35)

IL6 high (n = 48)

p

IL8 low (n = 45)

IL8 high (n = 38)

p

Gender (male)

77 (92.7)

34 (97.1)

43 (89.5)

0.393

42 (93.3)

35 (92.1)

 > 0.999

Age (≥ 65 years)

42 (50.6)

18 (51.4)

24 (50.0)

 > 0.999

24 (53.3)

18 (47.3)

0.588

Race (White)

74 (89.1)

32 (91.4)

42 (87.5)

0.727

41 (91.1)

33 (86.8)

0.725

ECOG

       

 0

58 (69.8)

28 (80.0)

30 (62.5)

0.111

35 (77.8)

23 (60.5)

0.122

 1

24 (28.9)

7 (20.0)

17 (35.4)

 

10 (22.2)

14 (36.8)

 

 Missing

1 (1.2)

 

1 (2.1)

  

1 (2.6)

 

Liver cirrhosis (yes)

70 (84.3)

26 (74.2)

44 (91.6)

0.065

34 (75.5)

36 (94.7)

0.03

HCC etiology

       

 Hepatitis B

4 (4.8)

2 (5.7)

2 (4.1)

 > 0.999

3 (6.6)

1 (2.6)

0.621

 Hepatitis C

19 (22.8)

6 (17.1)

13 (27.0)

0.287

10 (22.2)

9 (23.6)

0.874

 Alcohol

44 (53)

15 (42.8)

29 (60.4)

0.113

18 (40)

26 (68.4)

0.009

Previous TACE

18 (15.6)

9 (25.7)

9 (18.7)

0.447

11 (24.4)

7 (18.4)

0.507

Diffuse disease (≥ 10 lesion)

48 (49.3)

20 (57.1)

28 (58.3)

0.913

22 (48.8)

26 (68.4)

0.072

Median (mean) target lesion size, mm

68 (72.4)

66 (74.2)

70 (69.8)

0.65

56 (65.8)

73.5 (80.1)

0.13

Portal vein infiltration

31 (37.3)

9 (25.7)

22 (45.8)

0.061

11 (24.4)

20 (52.6)

0.008

Extrahepatic spread

21 (25.3)

6 (17.1)

15 (31.2)

0.144

11 (24.4)

10 (26.3)

0.845

Child–Pugh

       

 A

77 (92.7)

34 (97.1)

43 (89.5)

0.393

44 (97.7)

33 (86.8)

0.088

 B

6 (7.2)

1 (2.8)

5 (10.4)

 

1 (2.2)

5 (13.1)

 

BCLC

       

 B

26 (31.3)

15 (42.8)

11 (22.9)

0.053

16 (35.6)

10 (26.3)

0.365

 C

57 (68.6)

20 (57.1)

37 (77.0)

 

29 (64.4)

28 (73.6)

 

Up-to-7 criteria (outside)

71 (85.5)

29 (82.8)

42 (87.5)

0.552

37 (82.2)

34 (89.4)

0.532

Total bilirubin ≥ 17 µmol/L

25 (30.1)

6 (17.1)

19 (39.5)

0.027

11 (24.4)

14 (36.8)

0.22

Albumin < 36 g/L

20 (24.1)

3 (8.5)

17 (35.4)

0.004

7 (15.5)

13 (34.2)

0.054

AFP ≥ 400

29 (34.9)

11 (31.4)

18 (37.5)

0.519

13 (28.8)

16 (42.1)

0.235

mALBI grade (2b and 3)

21 (25.3)

3 (8.5)

18 (37.5)

0.002

8 (17.7)

13 (34.2)

0.129

  1. Bold type indicates statistical significance;
  2. IL, interleukin; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; mALBI, modified albumin–bilirubin; TACE, transarterial chemoembolization; BCLC, Barcelona Clinic Liver Cancer; AFP, alfa fetoprotein